- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT03437733
Multi-electrode Radiofrequency Balloon Catheter Use for the Isolation of the Pulmonary Veins. (SHINE)
1. Dezember 2020 aktualisiert von: Biosense Webster, Inc.
This clinical investigation is a prospective, multicenter, single arm clinical evaluation utilizing the multi-electrode radiofrequency balloon catheter and the multi-electrode circular diagnostic catheter.
Studienübersicht
Status
Abgeschlossen
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
The objective of this clinical investigation is to assess the safety and acute effectiveness of the multi-electrode radiofrequency balloon catheter and multi-electrode circular diagnostic catheter when used for the isolation of the pulmonary veins in the treatment of Paroxysmal Atrial Fibrillation (PAF).
Studientyp
Interventionell
Einschreibung (Tatsächlich)
98
Phase
- Unzutreffend
Kontakte und Standorte
Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.
Studienorte
-
-
-
Bari, Italien
- Ospedale "F. Miulli"
-
Milan, Italien
- Centro Cardiologico Monzino
-
-
-
-
-
Prague, Tschechien
- Na Homolce Hospital
-
-
-
-
-
Liverpool, Vereinigtes Königreich
- Liverpool Heart and Chest Hospital
-
London, Vereinigtes Königreich
- Bart's Health NHS Trust
-
-
Teilnahmekriterien
Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.
Zulassungskriterien
Studienberechtigtes Alter
18 Jahre bis 75 Jahre (Erwachsene, Älterer Erwachsener)
Akzeptiert gesunde Freiwillige
Nein
Studienberechtigte Geschlechter
Alle
Beschreibung
Inclusion Criteria:
- Diagnosed with Symptomatic Paroxysmal AF.
- Selected for atrial fibrillation (AF) ablation procedure for pulmonary vein isolation.
- Able and willing to comply with uninterrupted per-protocol anticoagulation requirements
- Age 18-75 years.
- Able and willing to comply with all pre-, post- and follow-up testing and requirements.
- Signed Patient Informed Consent Form.
Exclusion Criteria:
- AF secondary to electrolyte imbalance, thyroid disease, or reversible or non-cardiac cause.
- Previous surgical or catheter ablation for AF.
- Anticipated to receive ablation outside the PV ostia and Cavo-triscuspid-isthmus (CTI) region
- Previously diagnosed with persistent, longstanding AF and/or continuous AF > 7 days, or > 48 hrs terminated by cardioversion.
- Any percutaneous coronary intervention (PCI) within the past 2 months.
- Valve repair or replacement and presence of a prosthetic valve.
- Any carotid stenting or endarterectomy.
- Coronary artery bypass grafting (CABG), cardiac surgery (e.g. ventriculotomy, atriotomy), or valvular cardiac surgical or percutaneous procedure within the past 6 months.
- Documented left atrium (LA) thrombus on baseline/pre-procedure imaging.
- LA antero posterior diameter > 50 mm
- Any PV with a diameter ≥ 26 mm
- Left Ventricular Ejection Fraction (LVEF) < 40%.
- Contraindication to anticoagulation (e.g. heparin).
- History of blood clotting or bleeding abnormalities.
- Myocardial infarction within the past 2 months.
- Documented thromboembolic event [including transient ischemic attack(TIA)] within the past 12 months.
- Rheumatic Heart Disease.
- Uncontrolled heart failure or New York Heart Association (NYHA) function class III or IV.
- Awaiting cardiac transplantation or other cardiac surgery within the next 12 months.
- Unstable angina.
- Acute illness or active systemic infection or sepsis.
- Diagnosed atrial myxoma or interatrial baffle or patch.
- Presence of implanted pacemaker or implantable cardioverter defibrillator (ICD).
- Significant pulmonary disease, (e.g. restrictive pulmonary disease, constrictive or chronic obstructive pulmonary disease) or any other disease or malfunction of the lungs or respiratory system that produces chronic symptoms.
- Significant congenital anomaly or medical problem that, in the opinion of the investigator, would preclude enrollment in this study.
- Women who are pregnant (as evidenced by pregnancy test if pre-menopausal), lactating, or who are of child bearing age and plan on becoming pregnant during the course of the clinical investigation.
- Enrollment in an investigational study evaluating another device, biologic, or drug.
- Has known pulmonary vein stenosis.
- Presence of intramural thrombus, tumor or other abnormality that precludes vascular access, or manipulation of the catheter.
- Presence of an Inferior Vena Cava (IVC) filter
- Presence of a condition that precludes vascular access.
- Life expectancy or other disease processes likely to limit survival to less than 12 months.
- Presenting contra-indication for the devices (e.g. transthoracic echocardiography (TTE), CT, etc.) used in the study, as indicated in the respective instructions for use.
Categorized as a vulnerable population and requires special treatment with respect to safeguards of well-being
Additional exclusion criteria for Neurological Assessment Evaluable (NAE) subjects:
- Contraindication to use of contrast agents for MRI such as advanced renal disease, etc. (at PI discretion)
- Presence of iron-containing metal fragments in the body
- Unresolved pre-existing neurological deficit.
Studienplan
Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: N / A
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
---|---|
Experimental: Intervention
Ablation with Multi-electrode Radiofrequency (RF) Balloon Catheter
|
RF ablation using multi-electrode radiofrequency balloon catheter and multi-electrode circular diagnostic catheter
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Number of Participants With Early Onset Primary Adverse Events (PAEs): Death, Atrio-esophageal Fistula and Pulmonary Vein Stenosis
Zeitfenster: Up to 90 days (post initial mapping and ablation procedure)
|
A Primary AEs is an event which occurred within 90 days following initial ablation procedure.
Primary AEs included: Death, atrio-esophageal fistula, and pulmonary vein stenosis.
|
Up to 90 days (post initial mapping and ablation procedure)
|
Number of Participants With Early Onset PAEs: Myocardial Infraction, Cardiac Tamponade/Perforation, Thromboembolism, Stroke/Cerebrovascular Accident, Transient Ischemic Attack, Phrenic Nerve Paralysis, and Major Vascular Access Complication/Bleeding
Zeitfenster: Up to 7 days (post initial mapping and ablation procedure)
|
A Primary AEs is an event which occurred within the first week (7 days of the initial mapping and ablation procedure) which included myocardial infraction (MI), cardiac tamponade (CT)/perforation, thromboembolism, stroke/cerebrovascular accident (CVA), Transient ischemic attack (TIA), phrenic nerve paralysis (PNP), and major vascular access complication (MVAC)/bleeding following initial ablation procedure.
|
Up to 7 days (post initial mapping and ablation procedure)
|
Percentage of Participants With Acute Procedural Success
Zeitfenster: Day 1
|
Acute procedural success is defined as confirmation of entrance block in treated pulmonary veins (PV) after adenosine and/or isoproterenol challenge (with or without the use of a focal catheter).
|
Day 1
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Number of Participants With Individual PAE From Primary Composite
Zeitfenster: Up to 7 days for MI, CT/perforation, thromboembolism, stroke/CVA, TIA, PNP and MVAC (initial mapping and ablation procedure) and up to 90 days for death, AE fistula, and PVST (post procedure)
|
A Primary AEs is an event which occurred within the first week (7 days of the initial mapping and ablation procedure) which included death, atrio-esophageal fistula (AE fistula) and pulmonary vein stenosis (PVST); and up to 90 days post procedure which included myocardial infraction (MI), cardiac tamponade (CT)/perforation, thromboembolism, stroke/cerebrovascular accident (CVA), Transient ischemic attack (TIA), phrenic nerve paralysis (PNP), and major vascular access complication (MVAC)/bleeding following initial ablation procedure.
|
Up to 7 days for MI, CT/perforation, thromboembolism, stroke/CVA, TIA, PNP and MVAC (initial mapping and ablation procedure) and up to 90 days for death, AE fistula, and PVST (post procedure)
|
Number of Participants With Serious Adverse Device Effects (SADEs)
Zeitfenster: Up to 405 Days
|
An adverse device effect is an adverse event related to the to the device and or the procedure of the investigational medical device.
SADE is an adverse device effect that has resulted in any of the consequences characteristic of an SAE.
|
Up to 405 Days
|
Number of Participants With Serious Non-primary Adverse Events Within 7 Days (Early Onset), 8-30 Days (Peri-procedural) and Greater Than or Equal to (>=) 31 Days (Late Onset) of Initial Ablation Procedure
Zeitfenster: Within 7 Days (Early Onset), 8-30 Days (Peri-procedural) and >=31 Days (Late Onset) of Initial Ablation Procedure (Up to 405 Days)
|
Serious non-primary adverse event was defined as SAE that are not primary adverse events.
Primary AEs included: Death, atrio-esophageal fistula, and pulmonary vein stenosis.
|
Within 7 Days (Early Onset), 8-30 Days (Peri-procedural) and >=31 Days (Late Onset) of Initial Ablation Procedure (Up to 405 Days)
|
Number of Participants With Non-serious Adverse Events
Zeitfenster: Up to 405 Days
|
An AE is any untoward medical occurrence in participants whether or not related to the investigational medical device.
|
Up to 405 Days
|
Number of Participants With Pre-and Post-ablation Asymptomatic and Symptomatic Cerebral Emboli
Zeitfenster: Pre-procedure, at Discharge, 1 Month and at unscheduled visit (Up to 405 Days)
|
Number of participants with pre-and post-ablation asymptomatic and symptomatic cerebral emboli was reported.
|
Pre-procedure, at Discharge, 1 Month and at unscheduled visit (Up to 405 Days)
|
Number of Participants With Symptomatic and Asymptomatic Cerebral Emboli
Zeitfenster: Up to 405 Days
|
Number of participants with symptomatic and asymptomatic cerebral emboli was reported
|
Up to 405 Days
|
Number of Participants With New or Worsening Neurologic Deficits
Zeitfenster: Pre-procedure, discharge, 1 Month, 3 Month and 6 Month
|
Number of participants with new or worsening neurologic deficits was reported.
|
Pre-procedure, discharge, 1 Month, 3 Month and 6 Month
|
Number of Participants With NIHSS Scores
Zeitfenster: Pre-procedure and at discharge (Up to 405 Days)
|
The National Institutes of Health Stroke Scale, or NIH Stroke Scale (NIHSS) is a tool used to objectively quantify the impairment caused by a stroke.
The NIHSS is composed of 11 items, each of which scores a specific ability between 0 and 4. For each item, a score of 0 typically indicates normal function in that specific ability, while a higher score is indicative of some level of impairment.
The individual scores from each item are summed to calculate a patient's total NIHSS score.
The patient's total NIHSS score ranges from 0 (minimum) - 42 (maximum).
Score 0 (no stroke symptoms); 1 - 4 (Minor stroke); 5-15 (Moderate stroke); 16-20 (Moderate to severe stroke); and 21-42 (Severe stroke).
|
Pre-procedure and at discharge (Up to 405 Days)
|
Number of Participants With MoCA Scores
Zeitfenster: Up to 405 Days
|
Montreal Cognitive Assessment (MoCA) is used for detecting cognitive impairment, the scores range from 0 to 30.
A score of 26 or higher is considered normal, patients with mild cognitive impairment (MCI) were scored an average of 22 and patients with significant cognitive impairment (SCI) were scored an average of 16.
|
Up to 405 Days
|
Number of Participants With Hospitalization for Cardiovascular Events
Zeitfenster: Within 7 Days (Early Onset), 8-30 Days (Peri-procedural) and >=31 Days (Late Onset) of Initial Ablation Procedure (Up to 405 Days)
|
Hospitalization was defined as prolonged stay greater than or equal to (>=) 2 nights post index procedure or in-patient stay not concurrent with index procedure >= 1 calendar day.
Hospitalization included cardiovascular events due to any cause post index procedure, regardless of protocol-defined serious/non-serious adverse events (AEs) or not.
Hence this data was not contributed in serious Adverse events until met the AE definition.
|
Within 7 Days (Early Onset), 8-30 Days (Peri-procedural) and >=31 Days (Late Onset) of Initial Ablation Procedure (Up to 405 Days)
|
Percentage of Participants With PVI Touch-up by Balloon and/or Focal Catheter Among All Targeted Veins and by Participants
Zeitfenster: Up to 405 Days
|
Percentage of participants with PVI touch-up by balloon and/or focal catheter among all targeted veins and by participants was reported.
Most of the participants were ablated by Balloon catheter only while one participant was ablated with both Balloon and Focal catheters.
|
Up to 405 Days
|
Percentage of Participants With Use of Focal Catheter Ablation for Non-PV Triggers
Zeitfenster: Up to 405 Days
|
Percentage of participants with use of focal catheter ablation for non-PV triggers was reported.
|
Up to 405 Days
|
Percentage of Participants With Freedom From Documented Atrial Fibrillation (AF), Atrial Tachycardia (AT), or Atypical (Left Side) Atrial Flutter (AFL) Episodes or Documented Symptomatic AF/AT/AFL
Zeitfenster: Up to 6 Months
|
Percentage of participants with six-month arrythmia recurrence [defined as freedom from documented symptomatic or asymptomatic atrial fibrillation (AF), atrial tachycardia (AT), or atypical (left side) atrial flutter (AFL) episodes (episodes >30 seconds on arrhythmia monitoring device from Day 91 to 180 post the index procedure)] was reported.
|
Up to 6 Months
|
Percentage of Participants With Freedom From Documented, AF, AT, or Atypical (Left Side) AFL Episodes or Documented Symptomatic AF/AT/AFL
Zeitfenster: Up to 12 Months
|
Twelve-month Arrythmia recurrence is defined as a documented symptomatic or asymptomatic episode >30 seconds on an arrhythmia monitoring device between day 91 to 365 post the index procedure.
|
Up to 12 Months
|
Mitarbeiter und Ermittler
Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.
Sponsor
Publikationen und hilfreiche Links
Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.
Studienaufzeichnungsdaten
Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.
Haupttermine studieren
Studienbeginn (Tatsächlich)
28. Februar 2018
Primärer Abschluss (Tatsächlich)
1. Februar 2019
Studienabschluss (Tatsächlich)
17. Oktober 2019
Studienanmeldedaten
Zuerst eingereicht
13. Februar 2018
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
13. Februar 2018
Zuerst gepostet (Tatsächlich)
19. Februar 2018
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
22. Dezember 2020
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
1. Dezember 2020
Zuletzt verifiziert
1. November 2020
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- BWI_2017_01
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Nein
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Ja
Produkt, das in den USA hergestellt und aus den USA exportiert wird
Ja
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Paroxysmales Vorhofflimmern
-
Erasmus Medical CenterUnbekanntTachykardie, supraventrikulär | Tachykardie; Paroxysmal, supraventrikulärNiederlande
-
IRCCS Policlinico S. MatteoUniversity of Pavia; Azienda Regionale Emergenza Urgenza (AREU)RekrutierungAußerklinischer Herzstillstand | Ventrikuläre Fibrillation anhaltendItalien
-
Aurora Health CareNoch keine RekrutierungVorhofflimmern | Tachykardie atrial | Vorhofflattern mit schneller ventrikulärer ReaktionVereinigte Staaten
-
Ablacon, Inc.RekrutierungVorhofflimmern | Arrhythmien, Herz | Arrhythmie | Vorhofflattern | Vorhofflimmern, anhaltend | Atriale Tachykardie | Atriale Arrhythmie | Vorhofflimmern paroxysmal | Vorhofflimmern, paroxysmal oder anhaltendVereinigte Staaten, Belgien, Niederlande, Tschechien
-
The Hospital for Sick ChildrenLabatt Family Heart CentreRekrutierungVorhofflattern | Tachykardie, supraventrikulär | Tachykardie, AV-Knoten-Wiedereintritt | Tachykardie atrial | Tachykardie, reziprok | Tachykardie, paroxysmal | Fetaler Hydrops | Tachykardie, atriale EktopieVereinigte Staaten, Hongkong, Kanada, Niederlande, Schweden, Australien, Brasilien, Finnland, Frankreich, Russische Föderation, Spanien, Tschechien, Schweiz, Vereinigtes Königreich
-
University Hospital, GrenobleNoch keine RekrutierungVorhofflimmern paroxysmal
-
National Medical Research Center for Cardiology...RekrutierungVorhofflimmern paroxysmalRussische Föderation
-
Beijing Anzhen HospitalHeart Health Research CenterRekrutierungVorhofflimmern | Vorhofflimmern paroxysmalChina
-
University of UtahOhio State UniversityRekrutierungVorhofflimmern paroxysmalVereinigte Staaten
-
Brigham and Women's HospitalBoston Scientific CorporationNoch keine RekrutierungVorhofflimmern paroxysmalVereinigte Staaten
Klinische Studien zur Radiofrequency Ablation
-
Thermedical, Inc.Noch keine RekrutierungRefraktäre ventrikuläre TachykardieVereinigte Staaten, Kanada
-
Thermedical, Inc.National Heart, Lung, and Blood Institute (NHLBI)AbgeschlossenHerzkrankheiten | Herz-Kreislauf-Erkrankungen | Ventrikuläre Tachykardie | ArrhythmieVereinigte Staaten
-
Nimbus Concepts, LLCAbgeschlossenSchmerzen im unteren RückenVereinigte Staaten
-
Shanghai Chest HospitalUnbekannt
-
Eastbourne General HospitalUnbekanntAnhaltendes VorhofflimmernVereinigtes Königreich
-
Taipei Medical University HospitalRekrutierungChronische Rückenschmerzen | FacettengelenksyndromTaiwan
-
The Second Hospital of Hebei Medical UniversityAbgeschlossenAnhaltendes VorhofflimmernChina
-
Deutsches Herzzentrum MuenchenCryoCath Technologies Inc.AbgeschlossenAV-Knoten-Reentry-TachykardieDeutschland
-
University of ManchesterManchester University NHS Foundation TrustZurückgezogen
-
China National Center for Cardiovascular DiseasesRekrutierungAnhaltendes VorhofflimmernChina